Skip to main content Skip to main navigation menu Skip to site footer

Association between patient with muscle-invasive bladder cancer with the incidence of urinary tract infection in Karawang Regional Hospital: a single center study

Abstract

Background: Several studies link urinary tract infection (UTI) and bladder cancer. However, the association between bladder cancer muscle invasiveness and the incidence of UTI is not known

Objective: This study aimed to study the association between the occurrence of UTI in bladder cancer and the severity of the bladder cancer, specifically in a patient admitted to Karawang regional hospital, Indonesia.

Material and Methods: This is a single-center retrospective case control. Data were obtained through medical records of the patient admitted with bladder cancer in Karawang Regional Hospital from 2019-2021. Diagnosis of Non-muscle invasive Bladder cancer (NMIBC)/Muscle-invasive Bladder Cancer (MIBC) and UTI were all obtained through medical records. Binary logistic regression analysis was used to determine the odds ratio between these variables and the incidence of UTI

Result: A total of 59 samples were obtained. 57.7% were males, and 42.3% were females, with a mean age of 59 years and distributed into two groups, NMIBC/MIBC. There are also no significant gender and age difference between groups. Our data showed no significant association between bladder cancer muscle invasiveness and the incidence of UTI (OR=1.67; 95%CI 0.218-12.7; p=0.622). Subgroup analysis with different gender also yields no significant result.

Conclusion: UTI incidence increased in MIBC patients compared to NMIBC, but it is not statistically significant.

 

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May 1;71(3):209–49. Available from: https://doi.org/10.3322/caac.21660
  2. The Global Cancer Observatory. Cancer Incident in Indonesia. Int Agency Res Cancer [Internet]. 2020;858:1–2. Available from: http://dx.doi.org/10.4135/9781412963855.n637/
  3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS). Eur Urol. 2021;81(1):P75-94. Available from: https://doi.org/10.1016/j.eururo.2021.08.010
  4. Vermeulen SH, Hanum N, Grotenhuis AJ, Castaño-Vinyals G, van der Heijden AG, Aben KK, et al. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer. 2015;112(3):594–600. Available from: https://doi.org/ 10.1038/bjc.2014.601
  5. Bayne CE, Farah D, Herbst KW, Hsieh MH. Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis. World J Urol. 2018;36(8):1181–90. Available from: http://dx.doi.org/10.1007/s00345-018-2257-z
  6. Dobbs RW, Hugar LA, Revenig LM, Al-Qassab U, Petros JA, Ritenour CW, et al. Incidence and clinical characteristics of lower urinary tract symptoms as a presenting symptom for patients with newly diagnosed bladder cancer. Int Braz J Urol. 2014;40(2):198–203. Available from: http://dx.doi.org/10.1590/s1677-5538.ibju.2014.02.09
  7. Custovic A, Smajlovic J, Hadzic S, Ahmetagic S, Tihic N, Hadzagic H. Epidemiological surveillance of bacterial nosocomial infections in the surgical intensive care unit. Mater Sociomed. 2014;26(1):7–11. Available from: http://dx.doi.org/10.5455/msm.2014.26.7-11
  8. Observatory GC. Indonesia Cancer Situation GLOBOCAN 2020. World Heal Organ. 2020;
  9. Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of Urothelial Carcinoma and The New “World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016.” Eur Urol Focus. 2019;5(3):457–66. Available from: http://dx.doi.org/10.1016/j.euf.2018.01.003
  10. Witjes J a, Bruins H, Compérat E, Cowan NC, Efstathio J, Santis M De, et al. EAU Guideline on Muscle-Invasive and Metastatic Bladder Cancer. Eur Urol. 2021;79(1):82-104. Available from: http://dx.doi.org/10.1016/j.eururo.2020.03.055
  11. GLOBOCAN. Global Bladder Cancer Statistics. WHO [Internet]. 2020;1–2. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf
  12. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007 Jul;14(7):1237–43. Available from: http://dx.doi.org/10.1038/sj.cdd.4402148
  13. Manda K, Glasow A, Paape D, Hildebrandt G. Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells. Front Oncol. 2012;2:102. Available from: http://dx.doi.org/10.3389/fonc.2012.00102
  14. Xavier VF, Gabrielli FCG, Ibrahim KY, Gomes MVS, Guimarães RGR, Abdala E, et al. Urinary infection or radiation cystitis? A prospective evaluation of urinary symptoms in patients submitted to pelvic radiotherapy. Clinics (Sao Paulo). 2019;74:e1388. Available from: http://dx.doi.org/10.6061/clinics/2019/1388
  15. Nio Y, Hirahara N, Minari Y, Iguchi C, Yamasawa K, Toga T, et al. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface. Anticancer Res. 2000;20(5A):3293–9.
  16. Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther. 2012 Aug;11(8):1809–19. Available from: http://dx.doi.org/10.1158/1535-7163.mct-11-1014
  17. Aranda F, Bloy N, Pesquet J, Petit B, Chaba K, Sauvat A, et al. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene. 2015 Jun;34(23):3053–62. Available from: http://dx.doi.org/10.1038/onc.2014.234
  18. Huang SY, Wu CC, Hsieh MC, Rau KM, Chiang PH, Sung MT, et al. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma. Oncol. 2020;98(3):146–53. Available from: http://dx.doi.org/10.1159/000504393
  19. Anderson-Otunu O, Akhtar S. Chronic Infections of the Urinary Tract and Bladder Cancer Risk: a Systematic Review. Asian Pac J Cancer Prev. 2016;17(8):3805–7.
  20. Akhtar S, Al-Shammari A, Al-Abkal J. Chronic urinary tract infection and bladder carcinoma risk: a meta-analysis of case-control and cohort studies. World J Urol. 2018 Jun;36(6):839–48. Available from: http://dx.doi.org/10.1007/s00345-018-2206-x

How to Cite

Muhamad Iqbal Tafwid, & Achmad Rizky Herda Pratama. (2022). Association between patient with muscle-invasive bladder cancer with the incidence of urinary tract infection in Karawang Regional Hospital: a single center study. Bali Medical Journal, 11(3), 1494–1497. https://doi.org/10.15562/bmj.v11i3.3823

HTML
3

Total
1

Share

Search Panel

Muhamad Iqbal Tafwid
Google Scholar
Pubmed
BMJ Journal


Achmad Rizky Herda Pratama
Google Scholar
Pubmed
BMJ Journal